Cognitive enhancers in the treatment of substance use disorders: Clinical evidence
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Attenuation of drug reward has been the major focus of medication development in the addictions area to date. With the growth of research in the area of cognitive neuroscience, the importance of executive function and inhibitory cognitive control in addictive disorders is becoming increasingly apparent. An emerging strategy in the pharmacotherapy of addictions and other psychiatric disorders involves the use of medications that improve cognitive function. In particular, agents that facilitate inhibitory and attentional control, improve abstraction, planning and mental flexibility could be beneficial in the treatment of substance use disorders. Because there are multiple neurotransmitter systems involved in the regulation of cognitive function, agents from a number of drug classes have been tested. In particular, agents acting through the cholinergic, adrenergic and glutamatergic systems have shown potential for improving cognitive function in a number of psychiatric and neurologic disorders, but most of these agents have not been tested in the treatment of individuals with substance use disorders. This manuscript provides a review of clinical data supporting the use of the major classes of cognitive enhancing agents in substance use disorders. Agents that have shown promise in cognitive enhancement in other disorders, and have a theoretical or mechanistic rationale for application to substance use disorders are also highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The reorienting system of the human brain: from environment to theory of mind
Corbetta, M., Patel, G., & Shulman, G. L. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.017 · Cited by 3,889 · cited 1×
“As such, the LC–PFC system may comprise a critical link between dorsal and ventral frontoparietal attentional circuits that orient goal-driven versus stimulus-driven attention, respectively (Corbetta et al., 2008).”
BackgroundNeural systems of reinforcement for drug addiction: from actions to habits to compulsion
Everitt, B. J., & Robbins, T. W. (2005) · Nature Neuroscience · doi:10.1038/nn1579 · Cited by 3,785 · cited 1×
“…body of evidence indicates that mesolimbic dopamine neurons projecting from the ventral tegmental area to the nucleus accumbens are necessary for the acquisition of drug selfadministration, an essential step in the progression of addiction (Everitt and Robbins, 2005; Kalivas and O'Brien, 2008).”
BackgroundDopamine, learning and motivation.
Wise, R. A. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1406 · Cited by 3,379 · cited 1×
“This interaction is thought to be the basis for the reinforcing and addictive properties of nicotine (Balfour and Fagerstrom, 1996; Wise, 1996).”
BackgroundThe Neural Basis of Addiction: A Pathology of Motivation and Choice
Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529
The locus coeruleus and noradrenergic modulation of cognition
Sara, S. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2573 · Cited by 1,848 · cited 1×
“…from the locus coeruleus (LC) to the prefrontal cortex (PFC) are thought to exert a modulatory role on attention and working memory by facilitating functional connectivity between frontal cortex and other brain regions rather than by specific local effects in any one region (Sara, 2009).”
BackgroundAttentional bias in addictive behaviors: A review of its development, causes, and consequences
FIELD, M., & COX, W. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.03.030 · Cited by 1,376 · cited 1×
“A number of studies have demonstrated that attentional bias to drug-related cues is related to quantity and frequency of use and predictive of relapse to drugs of abuse (Field and Cox, 2008).”
BackgroundBymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli
Garavan, H., Pankiewicz, J., Bloom, A., Cho, J.-K., Sperry, L., Ross, T. J., Salmeron, B. J., Risinger, R., Kelley, D., & Stein, E. A. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1789 · Cited by 931 · cited 2×
“…that glutamatergic projections to the nucleus accumbens are critical for both stress and cocaine-primed reinstatement (McFarland et al., 2003; Park et al., 2002) and human imaging studies implicate glutamatergic pathways in the response to cocaine and cocaine cues (Garavan et al., 2000).”
BackgroundAtomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Left inferior frontal gyrus is critical for response inhibition
Swick, D., Ashley, V., & Turken, A. U. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-102 · Cited by 745 · cited 1×
“There are a number of brain regions within the PFC involved in inhibitory control including the orbitofrontal and anterior cingulate cortices, dorsolateral and dorsomedial PFC (Swick et al., 2008).”
BackgroundModafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713 · cited 2×
“Modafinil The non-amphetamine stimulant modafinil has received considerable attention as a potential psychotropic agent in several psychiatric disorders, including schizophrenia, ADHD, and more recently, cocaine and methamphetamine dependence (Ballon and Feifel, 2006; Minzenberg and Carter, 2008).”
BackgroundRemember the Future: Working Memory Training Decreases Delay Discounting Among Stimulant Addicts
Bickel, W. K., Yi, R., Landes, R. D., Hill, P. F., & Baxter, C. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.017 · Cited by 704 · cited 2×
“and treatment outcomes in substance-dependent individuals in treatment (Kiluk et al., 2010; Carroll et al., 2011; Bickel et al., 2011).”
BackgroundAdrenergic pharmacology and cognition: Focus on the prefrontal cortex
Ramos, B. P., & Arnsten, A. F. T. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.006 · Cited by 641
Kuczenski, R., & Segal, D. S. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052032.x · Cited by 623 · cited 1×
“Whereas methylphenidate is a selective inhibitor of the norepinephrine and dopamine transporters, amphetamine acts as both an inhibitor and substrate of norepinephrine, dopamine, and serotonin transporters and also promotes presynaptic release of all three neurotransmitters through its inhibition of the vesicular tran…”
BackgroundMichelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 12×
“Modafinil The non-amphetamine stimulant modafinil has received considerable attention as a potential psychotropic agent in several psychiatric disorders, including schizophrenia, ADHD, and more recently, cocaine and methamphetamine dependence (Ballon and Feifel, 2006; Minzenberg and Carter, 2008).”
BackgroundInfluentialNeurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans
Chamberlain, S. R., Müller, U., Blackwell, A. D., Clark, L., Robbins, T. W., & Sahakian, B. J. (2006) · Science · doi:10.1126/science.1121218 · Cited by 573 · cited 2×
“Effective in improving attention in both children and adults with ADHD (Michelson et al., 2002, 2003), atomoxetine also selectively improved response inhibition without affecting probabilistic learning in healthy volunteers (Chamberlain et al., 2006).”
BackgroundA meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510 · cited 2×
“Acute treatmentwith D-cycloserine (DCS), a partial glutamateNMDA receptor agonist active at the glycine binding site, enhances learning processesunderlying theacquisitionof theextinction of conditioned fear responding in animal models as well as in clinical populations of individuals with anxiety disorders (D'Souza et…”
BackgroundStimulants: Therapeutic Actions in ADHD
Arnsten, A. F. T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301164 · Cited by 473 · cited 2×
“Guanfacine, a selective agonist of the α-2A adrenergic receptor found in high density in the PFC, is another noradrenergic medication approved for treatment of ADHD in children (Ramos and Arnsten, 2007).”
BackgroundCognitive deficits predict low treatment retention in cocaine dependent patients
Aharonovich, E., Hasin, D. S., Brooks, A. C., Liu, X., Bisaga, A., & Nunes, E. V. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.08.003 · Cited by 397 · cited 1×
“Therefore, it is not surprising that individuals in treatment with compromised cognitive function have higher dropout rates and poorer treatment outcomes (Aharonovich et al., 2006, 2008; Fox et al., 2009).”
BackgroundA Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391 · cited 3×
“…outpatients, Dackis et al. (2005) found no effect of modafinil on study retention or CBT attendance but reported a significantly higher proportion of benzoylecgonine-negative urine drug screens inmodafinil-treated subjects as compared to the placebo-treated group (Dackis et al., 2005).”
BackgroundResultInfluentialLevkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387 · cited 1×
“These animal studies, coupled with encouraging preliminary human studies, led to a controlled trial of minocycline targeting cognition and negative symptoms in schizophrenia (Levkovitz et al., 2010).”
ResultTurner, D. C., Clark, L., Dowson, J., Robbins, T. W., & Sahakian, B. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.02.008 · Cited by 301
The neuropsychopharmacology of attention-deficit/hyperactivity disorder
Pliszka, S. R. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.026 · Cited by 276 · cited 3×
“Approved for use in children and adults with ADHD, both methylphenidate and amphetamine increase sustained attention, improve inhibitory control, and reduce impulsivity in ADHD, effects attributed to actions on norepinephrine and dopamine neurons projecting to the PFC (Arnsten, 2007; Pliszka, 2005).”
BackgroundBrennan, A. R., & Arnsten, A. F. T. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1417.007 · Cited by 267
Modafinil for the treatment of cocaine dependence
Anderson, A. L., Reid, M. S., Li, S.-H., Holmes, T., Shemanski, L., Slee, A., Smith, E. V., Kahn, R., Chiang, N., Vocci, F., et al. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.015 · Cited by 235 · cited 3×
“…trial of 210 treatment-seeking cocainedependent patients randomized to placebo or one of two doses (200 or 400 mg/day)ofmodafinil foundnosignificant effect ofmodafinil on study retention, counseling attendance, or cocaine use in the full sample over the 12-week study period (Anderson et al., 2009).”
BackgroundResultInfluentialVarenicline improves mood and cognition during smoking abstinence
Patterson, F., Jepson, C., Strasser, A. A., Loughead, J., Perkins, K. A., Gur, R. C., Frey, J. M., Siegel, S., & Lerman, C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.028 · Cited by 222 · cited 2×
“In another crossover study, smokers (n=67)exhibited improvedsustainedattention(Cohen's d 0.33) and working memory (Cohen's d 0.21) during abstinence after 21 days of varenicline as compared to placebo (Patterson et al., 2009).”
MethodInfluentialLevin, F. R., Evans, S. M., Brooks, D. J., & Garawi, F. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.07.004 · Cited by 220 · cited 2×
“…in treatment-seeking cocaine-dependent subjects with co-morbid ADHD, no significant treatment effect was observed in the overall sample, but subjects whose ADHD symptoms improved with methylphenidate reduced cocaine use significantly relative to placebo-treated subjects (Levin et al., 2007).”
BackgroundA double-blind, placebo-controlled trial of modafinil for cocaine dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Plebani, J. G., Pettinati, H. M., Sparkman, T., & O'Brien, C. P. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.12.014 · Cited by 187
Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders
Wilens, T. E., Adler, L. A., Weiss, M. D., Michelson, D., Ramsey, J. L., Moore, R. J., Renard, D., Brady, K. T., Trzepacz, P. T., Schuh, L. M., et al. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.02.009 · Cited by 171
Self-citationA double‐blind, placebo‐controlled trial of modafinil (200 mg/day) for methamphetamine dependence
Shearer, J., Darke, S., Rodgers, C., Slade, T., Van Beek, I., Lewis, J., Brady, D., McKetin, R., Mattick, R. P., & Wodak, A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02437.x · Cited by 159 · cited 6×
“Similarly, there was no advantage of modafinil in increasing participation in psychosocial counseling sessions (Shearer et al., 2009).”
BackgroundResultInfluentialEffects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial
Mooney, M. E., Herin, D. V., Schmitz, J. M., Moukaddam, N., Green, C. E., & Grabowski, J. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.10.016 · Cited by 124
Longo, M., Wickes, W., Smout, M., Harrison, S., Cahill, S., & White, J. M. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02717.x · Cited by 122
Guanfacine treatment of cognitive impairment in schizophrenia
Friedman, J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00249-4 · Cited by 113 · cited 2×
“, 1999), as well as enhancing attentional performance in subjects with schizophrenia (Friedman et al., 2001) suggests that guanfacine or related medications may warrant further study as cognitive enhancers in individuals with addictions.”
BackgroundN‐Acetylcysteine (NAC) in Young Marijuana Users: An Open‐Label Pilot Study
Gray, K. M., Watson, N. L., Carpenter, M. J., & LaRowe, S. D. (2010) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2009.00027.x · Cited by 109
Self-citationHeinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105 · cited 2×
“In each study, modafinil at daily doses of 200 mg (Shearer et al., 2009) and 400 mg (Heinzerling et al., 2010) failed to improve retention or reduce methamphetamine use in full sample analyses.”
BackgroundResultAbuse liability assessment of atomoxetine in a drug-abusing population
Jasinski, D. R., Faries, D. E., Moore, R. J., Schuh, L. M., & Allen, A. J. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.01.008 · Cited by 87 · cited 2×
“…research groups, atomoxetine exerted minimal stimulant-like subjective effects or abuse liability in human laboratory volunteers (Heil et al., 2002; Jasinski et al., 2008) and attenuated the euphoric subjective effects of dextroamphetamine (Sofuoglu and Sewell, 2009), though none of these studies…”
BackgroundKalechstein, A. D., De La Garza, II, & Newton, T. F. (2010) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2010.00052.x · Cited by 67 · cited 2×
“…study of 400 mg/day modafinil in nontreatment-seeking subjects with methamphetamine dependence tested sequentially at baseline and after each treatment condition, modafinil improved scores on a working memory task, but only in subjects with low baseline performance (Kalechstein et al., 2010).”
MethodD-cycloserine and cocaine cue reactivity: preliminary findings
Price, K. L., McRae-Clark, A. L., Saladin, M. E., Maria, M. M. M.-S., DeSantis, S. M., Back, S. E., & Brady, K. T. (2009) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990903384332 · Cited by 54
Self-citation
Cited by
Deficits in behavioural inhibition in substance abuse and addiction: a meta-analysis.
Smith, J. L., Mattick, R. P., Jamadar, S. D., & Iredale, J. M. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.009 · Cited by 546
Luijten, M., Machielsen, M., Veltman, D., Hester, R., de Haan, L., & Franken, I. (2014) · Journal of Psychiatry & Neuroscience · doi:10.1503/jpn.130052 · Cited by 356
Neuroscience of Addiction: Relevance to Prevention and Treatment
Volkow, N. D., & Boyle, M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17101174 · Cited by 322
Cognitive enhancement as a treatment for drug addictions
Sofuoglu, M., DeVito, E. E., Waters, A. J., & Carroll, K. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.021 · Cited by 298
Effects of non-invasive neurostimulation on craving: A meta-analysis
Jansen, J. M., Daams, J. G., Koeter, M. W. J., Veltman, D. J., van den Brink, W., & Goudriaan, A. E. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.07.009 · Cited by 284
Metadata
- Authors
- Brady, K. T., Gray, K. M., & Tolliver, B. K.
- Venue
- Pharmacology Biochemistry and Behavior
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 99
- Issue
- 2
- Pages
- 285-294
- ISSN
- 0091-3057 (ISSN-L)
- OpenAlex
- W1966785145
- Cited by
- 82
- References
- 39
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.